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Abstract
Introduction:  The  role  of  platelet  activation  in  allergic  inﬂammation  is  receiving  increasing
attention. Sublingual  immunotherapy  for  allergic  rhinitis  can  modify  the  immunological  process
to an  allergen,  rather  than  simply  treating  symptoms.
Objective:  The  aim  of  this  study  was  to  explore  the  role  of  platelet  activation  during  sublingual
immunotherapy  in  children  with  allergic  rhinitis.
Methods:  Forty-two  House  Dust  Mite  --  sensitized  children  with  allergic  rhinitis  were  enrolled
and received  House  Dust  Mite  allergen  extract  for  sublingual  immunotherapy  or  placebo.  Serum
of different  time  points  during  treatment  was  collected  and  used  for  detection  of  Platelet
Factor-4 and  Beta-Thromboglobulin  concentration  by  Enzyme-Linked  Immuno  Sorbent  Assay.
Results: Our  data  showed  decreased  expression  of  Platelet  Factor-4  and  Beta-Thromboglobulin
protein after  one  year’s  sublingual  immunotherapy.  In  addition,  the  decrease  of  symptom  scores
and serum  Platelet  Factor-4  and  Beta-Thromboglobulin  protein  concentrations  was  positively
related.
Conclusion:  During  sublingual  immunotherapy,  platelet  activation  was  inhibited  signiﬁcantly.
Our results  might  indicate  that  inhibition  of  platelet  activation  within  the  systemic  circulation
is an  important  mechanism  during  sublingual  immunotherapy.
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PALAVRAS-CHAVE
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Ativac¸ão  plaquetária;
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Fator  4  plaquetário;
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Efeito  da  imunoterapia  sublingual  sobre  a  atividade  plaquetária  em  crianc¸as com
rinite  alérgica
Resumo
Introduc¸ão:  O  papel  da  ativac¸ão  de  plaquetas  na  inﬂamac¸ão  alérgica  recebeu  atenc¸ão  cres-
cente. A  imunoterapia  sublingual  para  rinite  alérgica  pode  modiﬁcar  o  processo  imunológico  a
um alergeno,  em  vez  de  tratar  os  sintomas  simplesmente.
Objetivo:  O  objetivo  deste  estudo  foi  explorar  o  papel  da  ativac¸ão  plaquetária  durante  a
imunoterapia  sublingual  em  crianc¸as  com  rinite  alérgica.
Método:  Quarenta  e  duas  crianc¸as  com  rinite  alérgica  sensibilizadas  por  Ácaros  de  Poeira  Domi-
ciliar foram  inscritas  e  receberam  extrato  de  alergeno  de  Ácaros  de  Poeira  Domiciliar  para
imunoterapia  sublingual  ou  placebo.  O  soro  de  diferentes  pontos  no  tempo  durante  o  trata-
mento foi  recolhido  e  utilizado  para  a  detecc¸ão  de  fator  4  plaquetário  e  concentrac¸ão  de
beta-tromboglobulina  por  Ensaio  Imunoenzimático.
Resultados:  Nossos  dados  mostraram  diminuic¸ão  da  expressão  de  fator  4  plaquetário  e  pro-
teína beta-tromboglobulina  após  imunoterapia  sublingual  de  um  ano.  Além  disso,  a  diminuic¸ão
dos escores  de  sintomas  e  o  fator  4  plaquetário  sérico  e  concentrac¸ões  de  proteína  beta-
tromboglobulina  foram  relacionados  de  maneira  positiva.
Conclusão:  Durante  imunoterapia  sublingual,  a  ativac¸ão  plaquetária  foi  inibida  signiﬁcativa-
mente.  Os  nossos  resultados  podem  indicar  que  a  inibic¸ão  da  ativac¸ão  de  plaquetas  dentro  da
circulac¸ão sistêmica  é  um  mecanismo  importante  durante  imunoterapia  sublingual.
© 2016  Publicado  por  Elsevier  Editora  Ltda.  em  nome  de  Associac¸a˜o  Brasileira  de  Otorrino-
laringologia  e  Cirurgia  Ce´rvico-Facial.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY
(http://creativecommons.org/licenses/by/4.0/).
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ublingual  immunotherapy  (SLIT)  is  the  only  treatment  that
egulates  the  immunological  process  during  development
f  allergic  rhinitis  (AR),  rather  than  simply  treating  symp-
oms.1,2 However,  the  underlying  mechanisms  in  the  process
nd  potential  biomarkers  are  still  not  fully  characterized.
Platelet  activation  occurs  during  antigen-induced  airway
eactions  in  allergic  and  asthmatic  subjects.  Raised  lev-
ls  of  platelet-derived  mediators,  such  as  the  chemokines,
eta-Thromboglobulin  (BTG)  and  Platelet  Factor-4  (PF4),
re  observed  in  plasma  and  bronchoalveolar  lavage  ﬂuid  of
topic  individuals.  These  mediators  have  the  ability  to  acti-
ate  eosinophils,  increase  expression  of  Fc-IgG  and  Fc-IgE
eceptors,  and  stimulate  basophils  to  release  histamine.3--6
ince  SLIT  can  inhibit  allergic  inﬂammation  signiﬁcantly,  we
ostulate  that  SLIT  may  affect  platelet  activation  in  AR  chil-
ren.
In  the  current  study,  we  aimed  to  clarify  the  effect  of  SLIT
n  platelet  activation  of  AR  children  by  detecting  changes
f  serum  PF4  and  BTG  concentration.
ethods
atients
orty-two  children  aged  6--12  years  with  a  clinical  history
f  House  Dust  Mite  (HDM)  induced  AR  for  at  least  one
ear  were  enrolled.  Skin  Prick  Test  (SPT)  was  performed
o  screen  children  allergic  to  HDM.  Those  with  chronic  dis-
ases  (e.g.  asthma,  malnutrition,  anatomic  malformation
a
C
p
af  the  respiratory  system,  chronic  lung  disease,  heart  dis-
ase,  gastro-oesophageal  reﬂux  disease,  cystic  ﬁbrosis)  and
hose  with  a  history  of  chronic  drug  use  (e.g.  oral  or  nasal
orticosteroids,  antiepileptics,  immune  suppressives)  were
xcluded  from  the  study.  The  study  was  performed  with  the
pproval  of  local  ethics  committee  and  with  the  parent’s
ritten  informed  consent.
ublingual  immunotherapy  and  grouping
he  HDM  allergen  extract  for  SLIT  was  manufactured  by  Wol-
opharma  Biotechnology  Company  (Zhejiang,  China)  and
sed  in  the  form  of  drops  (n◦ 1,  1  mg/mL;  n◦ 2,  10  mg/mL;
◦ 3,  100  mg/mL  and  n◦ 4,  333  mg/mL).  According  to  the
anufacture’s  instruction,  the  patients  were  asked  to  take
ncreasing  doses  (from  n◦ 1  to  n◦ 3)  during  the  ﬁrst  three
eeks’  up-dosing  phase,  and  then  were  instructed  to  take
 drops  of  n◦ 4  solution  once  daily  during  the  maintenance
hase.  Drops  were  instructed  to  be  kept  under  the  tongue
or  2--3  min  before  swallowed.  Children  in  the  placebo  group
eceived  diluents  containing  50%  glycerol  and  50%  saline
uffer.  All  the  children  were  grouped  as  SLIT  (21  children)
nd  placebo  (21  children)  group  randomly.  The  drugs  were
abeled  with  patient  code  numbers,  and  the  investigator
ssigned  patients  in  a  sequential  randomized  fashion  to  a
tudy  code  number.  Individual  drug  bottles  were  identity
asked  in  order  that  both  patients  and  researchers  were
lind  to  treatment  assignment.  Study  blinding  was  preserved
t  the  study  sites  until  all  subjects  completed  the  study.
ompliance  with  medications  was  assessed  both  by  the
arent  questionnaire  and  by  measurement  of  drug  weight
dministered  every  second  week.
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Table  1  Demographic  characteristic  of  42  AR  children.
SLIT  group  Placebo  group
Number  21  21
Sex (male/female) 10/11  11/10
Age (months) 120.7  ±  44.0 123.0  ±  42.3
Duration  of  disease  (year)  5.2  ±  2.4  6.1  ±  3.7
Total IgE  (kU/L)  465  ±  226  513  ±  316
HDM speciﬁc  IgE  (kU/L)  45  ±  21  35  ±  18
Baseline  symptoms
Runny  nose  2.5  ±  0.3  2.1  ±  0.2
Sneezing  1.9  ±  0.1  1.7  ±  0.1
Blocked  nose 2.1  ±  0.2  1.8  ±  0.3
Itching  nose 1.5  ±  0.1 2.0  ±  0.4
Total  score  8.2  ±  0.6  7.9  ±  0.5
End-point  symptoms
Runny  nose  1.5  ±  0.2a,b 2.2  ±  0.3
Sneezing  1.4  ±  0.3a,b 1.5  ±  0.1
Blocked  nose  1.2  ±  0.1a,b 1.8  ±  0.1
Itching  nose  1.1  ±  0.2a,b 2.1  ±  0.2
Total  score  5.2  ±  0.3a,b 7.8  ±  0.2
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Symptom  scores
The  nose  symptoms  (runny  nose,  sneezing,  blocked  nose,
itching  nose)  were  scored  by  the  children  with  the  help  of
parents.  A  score  of  0  was  deﬁned  as  none  (no  symptoms
present),  a  score  of  1  was  deﬁned  as  mild  (mild  symp-
toms  that  do  not  interfere  with  any  activity),  a  score  of
2  was  deﬁned  as  moderate  (slightly  bothersome  symptoms
that  slightly  interfere  with  activity/nighttime  sleep),  and  a
score  of  3  was  deﬁned  as  severe  (bothersome  symptoms  that
interfere  with  activity/nighttime  sleep).7,8 The  scores  were
recorded  every  morning  daily  for  at  least  12  weeks  and  then
were  averaged.
Blood  samples  preparation  and  analysis
The  blood  samples  from  children  were  collected  between
11  am  and  2  pm  by  veinpuncture  method.  Serum  was
acquired  after  coagulation  of  the  blood  for  1--2  h  at  room
temperature  and  centrifuged  at  3000  ×  g  for  15  min  at
4 ◦C.  Serum  samples  were  stored  at  −80 ◦C  and  used  for
Enzyme-Linked  Immunosorbent  Assay  (ELISA).  Total  protein
concentration  was  determined  with  Bio-Rad  protein  assays
according  to  Bradford.  ELISA  kits  (Diagnostica  Stago,  France)
were  used  for  measuring  serum  PF4  and  BTG  concentration.
Statistical  analysis
All  data  were  expressed  as  mean  ±  SD.  Statistical  signif-
icances  between  different  groups  were  determined  using
nonparametric  Mann--Whitney  U  test.  The  Spearman  rank
correlation  test  was  used  to  analyze  the  correlation  between
symptom  score  and  PF4  or  BTG  concentration;  p  <  0.05  was
considered  as  signiﬁcant  difference.
Results
Demographic  characteristics  of  study  population
and clinical  outcome
This  study  was  conducted  with  42  children,  21  of  whom
enrolled  in  SLIT  group,  with  ages  ranging  between  72  and
144  months  (mean  age:  120.7  ±  44.0  months,  10  males),
and  21  of  whom  enrolled  in  placebo  group  with  ages  ran-
ging  between  75  and  141  months  (mean  age:  123.0  ±  42.3
months,  11  males).  The  age,  sex,  duration  of  disease,  base-
line  symptom  scores  between  two  groups  were  comparable
without  signiﬁcance.  The  SLIT  treatment  was  effective  and
the  symptoms  scores  decreased  signiﬁcantly  compared  with
both  placebo  group  and  baseline  symptom  scores  (Table  1).
Decreased  serum  PF4  and  BTG  protein  levels
during SLIT  treatment
The  serum  PF4  and  BTG  protein  expression  during  SLIT
treatment  were  signiﬁcantly  lower  than  those  in  placebo
group  after  6  months’  treatment  (PF4  3.2  ±  1.1  vs.
4.9  ±  1.2  IU/mL;  BTG  17.4  ±  4.3  vs.  23.2  ±  5.1  IU/mL)  and
this  trend  was  maintained  for  at  least  1  year  (PF4  1.3  ±  0.5
t
p
ia Compared with placebo group, p < 0.05.
b Compared with baselines symptom, p < 0.05.
s.  5.3  ±  1.7  IU/mL;  BTG  10.5  ±  3.2  vs.  21.6  ±  4.8  IU/mL)
Fig.  1A  and  B).
elationship  between  symptom  scores  and  serum
F4 and  BTG  protein  levels
o  explore  the  effect  of  platelet  activation  on  symptom
core,  we  analyzed  the  relationship  between  symptom
cores  and  serum  PF4  and  BTG  protein  levels  in  SLIT  group.
fter  one  year  of  treatment,  the  improvement  of  symptom
cores  was  positively  related  to  decrease  of  serum  PF4  and
TG  protein  levels  (p  =  0.65;  p  =  0.001;  p  =  0.51;  p  =  0.002)
Fig.  2).
iscussion
latelets  may  play  an  important  role  in  the  allergic  inﬂam-
atory  process  because  they  are  a  rich  source  of  biologically
ctive  materials  capable  of  inducing  or  augmenting  aller-
ic  inﬂammatory  responses.9--12,3 Such  materials  have  been
emonstrated  to  be  stored  in  alpha  granules,  which  are
hemokines  such  as  PF4  and  BTG.  However,  the  role  of
latelets  activation  in  SLIT  was  not  clear,  especially  in
hildren.
Our  results  showed  that  PF4  and  BTG  level  decreased
igniﬁcantly  after  6  months’  SLIT,  and  the  improvement
aintained  at  least  one  year.  Despite  decreased  PF4  and  BTG
evel  observed  after  3  months’  treatment,  no  statistically
igniﬁcant  changes  were  found.  Moreover,  the  improved
ymptom  scores  after  one  year  SLIT  was  positively  related
ith  decreases  of  PF4  and  BTG  level.  These  results  suggested
hat  SLIT  may  modify  the  allergic  process  by  inhibiting
latelet  function,  at  least  partially.
Consistent  with  our  results,  Kowal13 observed  increased
ntravascular  platelet  activation  in  House  Dust  Mite  allergic
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Figure  1  Serum  PF4  and  BTG  protein  expression  decreased  after  6  months’  SLIT  compared  with  control  group  and  baseline  level
with signiﬁcance.  The  decrease  maintained  at  least  one  year  without  rebound  (*p  <  0.05,  comparison  between  two  groups  and
baseline level;  ,  represents  for  placebo  group;  ,  represents  for  SLIT  group).
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Rigure  2  Positive  relationship  between  improvement  of  sym
hildren after  one  year’s  SLIT  in  active  treatment  group  (A  and
sthma  patients  undergoing  bronchial  allergen  challenge.
he  relationship  between  the  changes  of  platelet  activation
arkers  and  the  development  of  late  asthmatic  response
uggests  that  platelet  activation  within  the  circulation  is
ritical  for  the  development  of  chronic  allergic  inﬂamma-
ion.  Also,  Knauer14 has  demonstrated  signiﬁcant  changes
n  PF4  level  of  patients  with  pollen-induced  asthma  after
ronchial  provocation  to  ragweed  extract.
In  Alicja’s  study,15 they  found  that  plasma  PF4  level  in  the
atient  off--pollen  season  was  signiﬁcantly  lower  as  com-
ared  with  the  season  and  did  not  differ  signiﬁcantly  as
ompared  to  the  healthy  subjects.  Conversely,  in  their  two
ther  studies,16,17 the  results  suggested  that  PF4  and  BTG
evels  were  not  signiﬁcantly  different  between  the  patients
nd  healthy  subjects  after  immunotherapy.  Notably,  the
mmunotherapy  in  their  two  studies  lasted  only  6  months
nd  blood  sample  was  collected  immediately  after  maximum
ose  injection.  In  our  study,  the  SLIT  treatment  lasted  at
east  one  year  and  the  serum  was  sampled  at  different  time
oints.  We  found  that  decrease  of  serum  PF4  and  BTG  level
asted  at  least  one  year.  The  difference  between  our  and
licja’s  study  suggest  the  importance  of  maintenance  period
n  immunotherapy.  However,  a  small  number  of  patients  is
ne  of  limitations  in  our  study.  Future  studies  with  large  sam-
le  is  needed  to  further  clarify  the  role  of  PF4  and  BTG  in
LIT.  In  addition,  the  change  of  PF4  and  BTG  in  nasal  lavage
efore  and  after  SLIT  should  be  discussed  in  future  to  explore
he  local  effect  of  platelet  activation  in  mechanism  of  AR
nd  SLIT. scores  and  decrease  of  serum  PF4  and  BTG  protein  levels  of
onclusion
n  conclusion,  our  study  was  the  ﬁrst  to  show  the  changes  in
latelet  activity  in  vivo  in  AR  children  during  SLIT.  Our  results
ight  indicate  that  inhibition  of  platelet  activation  within
he  systemic  circulation  is  an  important  mechanism  during
LIT.  SLIT  may  improve  symptoms  by  inhibiting  platelet  acti-
ation  partially.
thical standards
he  authors  assert  that  all  procedures  contributing  to  this
ork  comply  with  the  ethical  standards  of  the  relevant
ational  and  institutional  guidelines  on  human  experimen-
ation  and  with  the  Helsinki  Declaration  of  1975,  as  revised
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